US Patent
US7645801 — Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Composition of Matter · Assigned to Alaven Pharmaceutical LLC · Expires 2027-07-24 · 1y remaining
Vulnerability score
22/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a packaged enema formulation containing substantially pure 5-ASA as the active ingredient for treating Inflammatory Bowel Disease (IBD).
USPTO Abstract
The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.